Pharmacokinetic and Pharmacodynamic Modeling of Tezepelumab to Guide Phase 3 Dose Selection for Patients With Severe Asthma. (16th January 2021)

• Record Type: Journal Article
• Authors: Ly, Neang; Zheng, Yanan; Griffiths, Janet M.; van der Merwe, Rene; Agoram, Balaji; Parnes, Jane R.; Roskos, Lorin
• Is Part Of: Journal of clinical pharmacology. Volume 61:Number 7(2021)
• Page Start: 901
• Page End: 912
• Publication Date: 2021-01-16
• Subjects: exposure‐response -- pharmacokinetic‐pharmacodynamic modeling -- severe asthma -- tezepelumab; Pharmacology -- Periodicals; Pharmacology -- Periodicals; Pharmacology, Clinical -- Periodicals; 615.1
• DOI: 10.1002/jcph.1803
• Languages: English
• ISSNs: 0091-2700

Abstract

Abstract: Tezepelumab is a human monoclonal antibody that blocks thymic stromal lymphopoietin, an epithelial cytokine involved in asthma pathogenesis. In the phase 2b PATHWAY study (ClinicalTrials.gov identifier: NCT02054130), tezepelumab significantly reduced exacerbations in adults with severe, uncontrolled asthma. We used pharmacokinetic (PK) and pharmacodynamic (PD) modeling to guide tezepelumab dose selection for phase 3 trials in patients with severe asthma. PK data from 7 clinical studies were used to develop a population PK model. Population PK‐PD models were developed to characterize the relationship between tezepelumab PK and asthma exacerbation rate (AER) and fractional exhaled nitric oxide (FeNO) levels (using phase 2b PD data only). Tezepelumab PK were well described by a 2‐compartment model with first‐order absorption; PK parameter estimates were consistent with those of other immunoglobulin G2 antibodies. PK‐PD models predicted that subcutaneous dosing at 210 mg every 4 weeks was associated with ≈90% of the maximum drug effect of tezepelumab on AER and FeNO; further dose increases were not expected to result in additional, clinically meaningful treatment benefit. No clinically significant covariates of treatment effects on AER and FeNO were identified. Population PK simulations, exposure‐response relationships and safety profiles of tezepelumab at doses up to 280 mg every 2 weeks suggested that no dose adjustment based on body weight or for adolescents was required. These results support the selection of 210 mg every 4 weeks subcutaneously as the dose for phase 3 studies of tezepelumab in adults and adolescents with severe asthma.